Antiviral treatment on Chronic Hepatitis B (CHB) patients with liver cirrhosis is compulsory and effective. Telbivudine, which is superior to lamivudine in the treatment of CHB,is considered to be appropriate for the antiviral treatment on CHB patients with liver cirrhosis.
Antiviral therapy on CHB patients with liver cirrhosis is compulsory and effective. Diseases development can be prevented or delayed if the virus is depressed successfully. Lamivudine is often used and usually has good efficacy. However, lamivudine resistance and virus mutation happens a lot. Telbivudine, which is superior to lamivudine in the treatment of CHB,is considered to be appropriate for the antiviral treatment on CHB patients with liver cirrhosis.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
120
telbivudine 600mg/d 96 weeks
the Fifth People's Hospital of Suzhou
Suzhou, Jiangsu, China
RECRUITINGSerum HBV DNA
serum HBV DNA negativity and decline from baseline at week 48
Time frame: 48 weeks
Serum HBeAg
rate of HBeAg seroconversion and HBeAg loss
Time frame: 48 weeks
Child-pugh score
the average decline of Child-pugh score at week 48 from baseline
Time frame: 48 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.